embarked on the study of various aspects of the organism's 'internal environment', focusing first on the reactions orchestrated by the autonomic nervous system and subsequently on the mechanisms brought into play by the central nervous system through behaviour. He often fondly recalled his admiration for Bernard, with whom he shared a sort of naif, i.e. a fearlessness in tackling problems of a complexity to give others pause and a rejection of the specialization later to characterize all sectors of biology and modern science.
The early years at the P asteur Institute and research on sulfa d rugs It was in Paris, therefore, that Bovet took his first steps as a pharmacologist, producing and elucidating the mechanism of numerous chemotherapeutic, antibacterial and antiprotozoic agents that were to revolutionize the perspectives of traditional therapy. Research at Ernest Fourneau's laboratory of therapeutic chemistry at the Pasteur Institute was inspired by the ideas of Paul Ehrlich. At the turn of the century, Ehrlich had launched the project of chemotherapy with the aim of discovering 'magic bullets', i.e. artificial chemical compounds capable of killing pathogenic microbes without damaging the host organism.
Bovet spoke at length about Ehrlich in an interview with the historian Gilberto Corbellini on the occasion of the publication of the Italian edition of his book on the history of sulfa drugs ( V ittoriasui microbi, Bollati Boringhieri, Torino 1990) . Like Fourneau, Bovet regarded Ehrlich as representing, together with Louis Pasteur, a fundamental historical and scientific point of reference for any understanding of the emergence of a rational approach in the fight against infective agents. However, Bovet admired Ehrlich not only for his scientific programme and approach, but also for the importance he attributed to luck in research work. According to the Ehrlich, four Gs were needed for the discovery of effective chemotherapeutic agents, the 'magic bullets': Geld (money), Geduld (patience), Geschick (ability) and Gliick (luck). Bovet also saw scientific research as a plexus of conditions impossible to control a priori and capable of suddenly giving rise to discovery. The following passage occurs in his book on the history of sulfa drugs:
One of the obstacles encountered by the historian of science is due in part to the protagonists themselves, who often cloak their discoveries with a veil of rigorous logic when they are actually the fruit of intuitive research. Closer investigation reveals something very different: artistic creation, play, the result of chance observations made at times during attempts to verify erroneous hypotheses.
In other words, Bovet felt that luck and chance played an important role, difficult though it may be to distinguish between luck and the researcher's intuitive ability to recognize that he is dealing with something new and hence to change tack with respect to his initial hypothesis.
In any case, the research on sulfa drugs carried out by Bovet and his colleagues at the Pasteur Institute went far beyond and substantially innovated Ehrlich's research programme in chemotherapy. After perfecting the first staining techniques for white corpuscles in 1877, Ehrlich had developed his project for chemotherapy precisely on the basis of the discovery of the chemically selective interaction between the synthetic staining materials and living cells, including microbes. Following this approach, in 1882 he succeeded in staining the tuberculosis bacillus isolated by Koch in 1876. From these results, Ehrlich argued that the chemical affinity between the staining molecules and the bacteria cells could be utilized to exploit whatever bactericidal properties the former might possess, or that these staining agents could be used as 'carriers' capable of transporting molecules toxic to the bacteria. This scientific programme bore fruit in 1906 when Paul Ehrlich produced Salvarsan, the first arsenic-based synthetic product active against the bacterium Treponema , the cause of syphilis.
Ehrlich's starting point was the theoretical assumption that the staining molecule represented the essential constituent of any compound capable of antimicrobial activity. This provides the key to the history of sulfa drugs, which began in 1906 when Paul Gelmo synthesized sulfamide during studies on the mechanism of the dying properties of staining agents. In 1932 the patent for a staining agent derived from sulfamide was registered by two chemists from Bayer IG Farben. Two years later, on 15 February 1935, the Deutsche medizinische Wochenschrift published an article by Gerhard Domagk demonstrating the effectiveness of the product, red Prontosil, against streptococcal infection. The German scientists belonging to Ehrlich's school attributed the product's effectiveness to its nature as a staining agent. At the same time, they could not account for the paradoxical fact that Prontosil was effective in vivo but totally inactive in vitro. The 'paradox' was cleared up by the work of Bovet and the chemists of the Pasteur Institute, the problem being essentially linked to the theoretical position maintained by Ehrlich. On the morning of 6 November 1935, after months of endeavour, Daniel Bovet, Federico Nitti and Jacques and Therese Trefouel succeeded in demonstrating that the antimicrobial effect obtained with Prontosil, i.e. with the coloured drug, could also be obtained with the white substance, i.e. sulfamide, used as the basis for the coloured compound. The paradox of Prontosil's inactivity in vitro was due to the fact that the drug remained devoid of antibacterial property as long as it retained its original chemical structure. Within the organism, however, the oxide-reducing processes led to the formation of two independent molecules, one of which, colourless p-aminophenylsulfamide, was effective against streptococcus.
These results were described by Bovet himself in the original article as follows:
After preparing and experimenting with various products resulting from the union of the diazo derivative of aminosulfanilamide with some alkylate mono-and poly-phenols, we realized that a number of derivatives differing greatly from Prontosil in their physical and chemical characteristics displayed analogous antistreptococcal power . . . For such highly different compounds to act in practically the same way, they must undergo a number of changes within the organism, the first of which would involve the breaking of the double link and the formation of aminophenylsulfamide. This hypothesis led us to examine the action of the p-aminophenylsulfamide hydrochloride (1162 F).
The therapeutic action of such a simple molecule -which is not a staining agent in itself -opens the door to a systematic study of chemotherapy comparable to that carried out in the field of pentavalent arsenic. [J. Trefouel, T. Trefouel, F. Nitti & D. Bovet, Activite du p-aminophenylsulfamide sur les infections streptococciques experimentales de la souris et du Lapin, Comptes Rendues de la Societe de Biologie 120, 756 (1935)] The therapeutic action of Prontosil was therefore not connected with its staining properties, as Domagk and the German school had thought. In somewhat less scientific terms than those used above, Bovet noted that the 'red car' had a 'white engine' ( chimie qui guerit, Peyot, Paris 1989).
To quote again from Bovet's book:
From the epistemological point of view, we had good reason to be astonished -as we still are -by the fact that initially empirical research based on an erroneous hypothesis -i.e. the therapeutic effectiveness of a staining agent -could lead to technically impeccable results, giving rise to a vast number of developments of both practical and theoretical value.
In 1936 the same group of researchers from the Pasteur Institute discovered that sulfa drugs do not kill bacteria but act as cytostatics. In 1940 Donald Woods and Paul Fildes were to demonstrate that the mechanism of sulfa drugs is based on their structural similarity to /rara-aminobenzoic acid (PABA), causing the compound to function as a competitive inhibitor. PABA is a component of folic acid, a metabolite essential for both prokaryote and mammal cells. However, while eukaryote cells utilize preformed folic acid obtained from diet, prokaryote cells use PABA to synthesize it themselves. This difference makes sulfa drugs effective agents of chemotherapy in that they can act as substitutes for PABA in the synthesizing of folic acid.
S ympathom im etic and sympatholitic drugs
The group's research activities were not, however, focused solely upon substances endowed with chemotherapeutic properties, but pursued the more general aim of elucidating the action mechanism of various substances, natural and synthesized, by following their metabolism within the organism or by formulating likely hypotheses. A similar strategy, based on following the 'path' of certain molecules through the tissues and liquids of the milieu interieur, was applied to the study of the derivatives of adrenaline, the substan secreted by the medulla of the adrenal glands. Bovet's now classic studies on the links between chemical composition, metabolism and pharmacodynamic action focused on the action of sympathomimetic and sympatholitic substances capable of simulating or having an antagonistic effect upon the action of adrenaline and noradrenaline. Whole series of molecules were studied to produce and perfect drugs capable of acting as vasodilators (especially on the coronaries), against bronchitis, asthma and hypertension, upon smooth musculature such as the uterine muscle, and so on.
Systematic research on the derivatives of adrenaline focused mainly on the hypertensive properties of the phenylethylamines. The sympathomimetic activity was described of various series of new derivatives, phenoxyethylamines, phenylethylsulfates and phenylethylenediamines. The new series of sympathomimetic derivatives not only broadened the range of adrenalinic substances but also proved illuminating from another viewpoint as representing so many links between what are conventionally known as sympathomimetic or adrenergic agents and their pharmacodynamic anta gonists, the sympatholitic agents. [Daniel Bovet, Curriculum Vitae submitted to the Chair of Pharmacology Selection Committee, 1963.] From 1933 to 1953, Bovet and his co-workers examined hundreds and hundreds of molecules synthesized above all by Foumeau's group and labelled F . . . , following their effects on the various areas of the vegetative nervous system in vitro and vivo.
As Bovet points out:
In a certain sense, it was the products themselves that decided the areas of pharmacological research my interests should be channelled towards. In 1933, for example, a student from Zurich came to work in my laboratory and conceived the idea of synthesizing a molecule that was to prove capable of neutralizing or reversing the effects of adrenaline (sympatheticolitic action). He had no a priori idea of the substance's physiological effects and, in fact, no interest in them. Letting myself be guided by this product, I discovered that it also possessed the function of neutralizing the effects of the histamine released during allergic reactions. The surprises were not over, however, as a few days later I discovered that it also had a hypnotic effect. In this way, my molecules led me to the problems of neuropharmacology, which led in turn to psychobiology. [Corbellini 1992] The antihistam ines
The first sympatholitic product (F.883, a derivative of 1,4-dioxane) had been studied by Bovet and Fourneau in the context of a research programme aimed at discovering anti-malarial drugs. This fact triggered a train of reflection that led Bovet to the discovery of antihistamines. The starting point of this research was the observation of similarities in the chemical structure of adrenaline, acetylcholine and histamine -three biogenic amines endowed with powerful pharmacological properties. Now, since the existence of para-sym patholitic substances had been known since the demonstration of the antispasmodic action of atropine in 1867, it was reasonable for Bovet to assume that a drug antagonistic to histamine could also exist.
Similarities as regards chemical structure, presence in humours and pharmacodynamic properties distinguish three highly active biogenic amines: acetylcholine, adrenaline and histamine. This linkage also prompted the idea that, just as there exist alkaloids capable of countering the effects of acetylcholine and sympatholitic poisons which neutralize or reverse the effects of adrenaline, there could also exist substances specifically antagonistic to histamine. [Daniel Bovet 1963] Histamine had been synthesized in 1907 and then isolated in ergot by Sir Henry Dale in 1910. In 1911, Dale and Patrick Laindlaw demonstrated its ability to cause anaphylactic contractions in the smooth musculature. While there was no definite proof in the 1930s that histamine was responsible for allergic reactions, Bovet's research supplied decisive support for this hypothesis. In 1937, Bovet and Anne Marie Staub described the antihistaminic action of thymoxyethyldiethylamine, a substance with anti-anaphylactic properties. The protection offered by antihistamines against anaphylactic shock provided definitive confirmation that histamine was the vasoactive substance most involved in this and in other allergic manifestations.
The analogy -frequently noted subsequent to Dale's observations -between allergic reactions and the effects of histamine intoxication led us to carry out experiments on anaphylactic shock based on the action of the histaminolithic amines belonging to the group of phenolic ethers and to determine the mechanism of their protective action . .. The antagonism exerted (by 929 F) must be linked to the protective action of this substance in the course of histamine intoxication in that the anti-shock action proceeds step by step with the histaminolithic action. In 1942, Bernard Halpem produced the first non-toxic derivative of diethylamine, and antihistamine therapy rapidly transformed the treatment of many allergic illnesses. In his introductory address when Bovet was awarded the Nobel Prize in 1957, the Swedish pharmacologist Bjorn Uvnas observed that his studies on histamine and on other biogenic amines had had considerable implications as regards both our understanding of the nervous system and their clinical applications.
The discovery of the function carried out by the biogenic amines as agents of chemical linkage within the organism opened up new horizons for research. Pharmacologists and chemists were thus enabled to produce new substances capable of imitating or inhibiting the action of the biogenic amines. .. . Daniel Bovet has concentrated his investigations on the problem of the pharmacological blocking caused by the previously mentioned biogenic amines and has succeeded in producing substances specifically inhibiting their effects. As long ago as 1937, Bovet and Staub successfully identified the first antagonist of histamine, thymoxyethyldiethylamine, capable of preventing anaphylactic shock in animals, which causes death if not neutralized. While it is true that this first antagonist was too toxic for clinical use, all the anti-histamines today used throughout the world to combat allergic symptoms can rightly be regarded as its derivatives.
Synthesized cu rare
Bovet and his team thus succeeded in discerning the links between the most disparate natural or synthesized molecules, in fathoming their physiological and pharmacological mechanisms. Their work on the relationships existing between the structure of a molecule and its function was something like the creation of a great fresco encompassing adrenaline and other sympathomimetic agents, the derivatives of dioxane, the amphetamines, the derivatives of lysergic acid, and so on.
This enormous labour of research and classification made it possible to 'follow the tracks' of molecules resembling each other but, at times, producing opposite effects at the level of the nerve receptors, which were still unknown at the time. The task, calling for the instincts of an authentic bloodhound, was described by Bovet and Bovet Nitti in Structure et activite pharmacodynamique des medicaments du systeme nerveux Karger, Basel, 1948), referred to jokingly by their co-workers as the Bible. Years after its publication, this Bible was still being used to track down molecular affinities and antagonisms of such complexity that the author of the monumental treatise was himself often obliged to consult it in order to pinpoint this or that minor molecule among the thousands and thousands studied by the group created by Ernest Fourneau at the Pasteur Institute.
Among the molecules studied, a highly important role was played by the synthesized forms of curare, active at the level of the cholinergic synapses between nerve and muscle. Ideally carrying on the work on curares started by the school of Claude Bernard and his pupil Vulpian, Bovet and Simone Courvoisier examined their paralysing action. These substances -alkaloids extracted from plants and still used today by the Indians in South and Central America to paralyse their prey -were brought into therapeutic use by Griffith and Johnson in 1942 in the form of d-tubocurarine, a term stemming from the tubes of bark in which the curare and the poisoned arrows were kept. In 1946 Bovet, Depierre and Courvoisier introduced the clinical use of gallamine or flaxedil, an extremely powerful synthesized derivative since used by generations of surgeons to relax the body muscles. This research was followed by numerous studies on the derivatives of succinylcholine carried out together with F. Bovet Nitti, S. Guarino, V.G. Longo and G.B. Marini-Bettolo at the Istituto Superiore di Sanita in Rome.
T he years in Italy
In 1947, Bovet accepted an invitation made by Domenico Marotta, director of the Istituto Superiore di Sanita, and moved to Rome with his wife Filomena to take charge of a large pharmacological laboratory which, like that at the Pasteur Institute, had been given the name of 'Therapeutic Chemistry'. The work of his new research team focused primarily on curare and on a vast range of substances acting on the central nervous system and on cerebral circulation. These marked a transitional stage on the path towards psychopharmacology and the biology of behaviour. When I joined Bovet's team in the early 1960s, he had been in charge for over a decade of the great laboratory at the Istituto di Sanita, whose various sections included chemistry, physiology, the electrical activity of the brain, cerebral circulation and behaviour. Having been awarded the Nobel Prize for medicine a few years earlier (1957) 'for discoveries regarding synthesized products that block the effects of a number of substances which form within and act upon the organism, in particular on the blood vessels and the musculature of the skeleton', Bovet was still at the peak of his scientific creativity, working in a laboratory crammed with foreign guests where it was possible to collaborate with other interesting research groups. Sir Ernst Boris Chain, another Nobel Prize winner, was also at the Istituto di Sanita as head of a team working on antibiotics and protein synthesis. Rita Levi Montalcini, later to win the Nobel Prize for her work on neurobiology, was a recent arrival. Numerous other scientists of real merit, from physicists to virologists, had also been drawn to the Institute by a climate of collaboration and a concentration of economic and scientific resources seldom found in Italy.
I met Bovet in his office, from which one glimpsed the laboratory and the shining glass manometers of the Warburg apparatus then used by his wife to gauge interactions between Cholinergic enzymes, drugs and nervous substrata through microvolumetric measurement of the gases. Though I was young and had only just graduated, Bovet spoke to me at length as though we were of equal scientific standing. His courtesy was somewhat disconcerting for anyone accustomed to the strongly hierarchical environment of Italian medicine at the time, where professors seldom had any contacts with their younger students or filtered them carefully through a complex pyramid of collaborators. Bovet's courtesy and openness were part of his charm. The absence in the laboratory of scientific hierarchies connected with position or age made his scientific activities similar in some respects to those of the English-speaking world.
The Istituto Superiore di Sanita was then still directed by Domenico Marotta and was unquestionably at the peak of its productivity. One could hardly have foreseen that it was soon to be hit by one of Italy's first scandals, a sordid business of political rivalry and career-hunting that led to traumatic intervention by the magistrates and brought research activities to a virtual standstill for years. When the scandal broke and brought down the Institute's director, Bovet and others stood up for Marotta. He could scarcely fathom the political and bureaucratic coils in which the Institute was being enmeshed and was deeply upset by the irrational nature of the situation, unlike the sanguine Chain, whose vehemently outspoken diatribes echoed through the corridors then walked by the young Stephen P.R. Rose.
Sir Ernst Chain left Italy for the Imperial College in London. Bovet, like others, guessed that life would be hard for the Institute, that the scandal would drag on for years and that life there would long be dominated by chronic rivalry and in-fighting. He thus decided to pack his bags and seek a new position, but quite underestimated the resistance his candidature would provoke in Italy's academic corporation. The author of hundreds of scientific publications and winner of the Nobel Prize with degrees honoris causa from numerous universities had a hard time trying to win a chair in pharmacology because of his 'lack of teaching experience'. However, in 1964 he was appointed professor of pharmacology at the University of Sassari in Sardinia, where he remained until the end of the 1960s, alternating his research activities between Sassari and the Brain Research Institute of the University of California in Los Angeles, where he had been invited as visiting professor of pharmacology by Sherman Mellinkoff, the Dean of the School of Medicine, and John D. French, Director of the Institute.
Bovet accepted this invitation with great enthusiasm, above all as he had for some time been engaged on research into behavioural genetics, using inbred strains of mice. These were then quite rare in Europe but readily available in the USA, where they were used in radiobiological research at Oak Ridge and immunogenetic studies at the Jackson Laboratory in Bar Harbour. He thus left for Los Angeles and worked for some years on the effects of cholinergic and adrenergic drugs on behaviour. Also involved was James L. McGaugh of the University of California at Irvine, who had worked with Bovet at the Institute in Rome. These studies were in fact to continue in Rome, where Bovet was invited in 1969 by the Science Faculty as Professor of Psychobiology, a new discipline for Italy, where idealistic schools and attitudes still predominated in psychology. In Rome, Bovet created the Laboratory of Psychobiology and Psychopharmacology of the Italian National Research Council, which he directed for ten years, still continuing his activities in the field of behaviour genetics.
From psychopharm acology to psy ch o bio lo g y As Bovet himself points out above, his research in the field of psychopharmacology and psychobiology is bound up with his studies on drugs acting upon the central nervous system, antihistamines, derivatives of chlorpromazine and adrenergic drugs. Starting from empirical observations as to how the effects of the different substances acting upon the nervous system and of the different psychotropic drugs vary from individual to individual, Bovet used the drugs as 'probes' to explore the nervous system and to gauge the variability of nerve structures and behaviour. These studies in psychopharm acology and psycho pharmacogenetics were soon to be flanked by studies into behavioural genetics based on the use of selected strains of rodent and inbred strains of mice. At Los Angeles and Sassari, he tackled the problem of the biological basis of memory from the viewpoint of individual differences and of the drugs that interfere with memory consolidation. One of the most interesting results of these studies involves the demonstration of the role played by genetic factors in conditioning certain aspects of learning and memory:
The findings reported here suggest that there are at least two reasons for using inbred strains in psychobiology, (i) the extreme behavioral homogeneity of the individuals belonging to the same strain, and (ii) the characteristic differences in behavioral traits of each strain. These inbred strains provide the psychobiologist with unlimited groups of individuals presenting a homogeneous adaptive beha viour. This availability is particularly important in view of previous difficulties and problems surrounding the establishment of learning and retention curves in laboratory animals. [D. Bovet, F. Bovet Nitti & A. Olivoerio, Science 163, 139-149 (1969)] The research carried out in the field of psychopharmacogenetics and behavioural genetics constituted an innovative approach that helped raise the problem of the biological factors determining behaviour at a time when psychobiological research was still in its infancy. When Bovet started work in this sector, experimental psychology was largely dominated by behaviourist theories claiming that all aspects of action -human or animal -could be accounted for in terms of stimulus and response, excluding any knowledge of the so-called cerebral 'black box'. By following a genetic approach, Bovet demonstrated that some behaviour patterns possess important biological components in that they depend on specific differences in the nervous system at the level of neurobiological structures, from nerve receptors to the extension of some cerebral nerve nuclei. He proposed that research in the neurosciences and psychobiology should be based on certain particular strains characterized by opposite phenotypes:
These three inbred strains of mice and their FI hybrids seem to be a very useful model for a genetic approach to the biological aspects of learning. The results of different biochemical estimates suggest in part that these lines and their crosses not only differ in behavior but also in some critical brain chemicals. Mandel and his group found large regional differences between these strains when their cholinergic and adrenergic levels and turnover were measured. Also the brain level of dopamine and cyclic AMP were found to be different in these strains. [D. Bovet, Strain differences and learning in the mouse. In A. Olivoerio (ed.), Genetics, environment and intelligence, North Holland, Amsterdam 1977, p. 83] This highly innovative genetic approach led to certain aspects of behaviour also being regarded as phenotypes and to the famous 'black box' revealing some of its contents. The approach was also connected with the important topic of the variability of neurobiological structures due to both genetic and epigenetic factors, since taken up by Gerald Edelman in his theory of 'neuronal Darwinism'.
An exam ple of SCIENTIFIC BRICOLAGE
The scientific trail blazed by Daniel Bovet is studded with numerous achievements despite the many obstacles encountered during his career. He never lost heart and overcame the crisis that broke at the Pasteur Institute at the end of the 1940s when Ernest Fourneau was accused of collaborationism and internal power struggles threatened the survival of the research group. He also weathered the storm at the Istituto Superiore di Sanita in Rome. In short, he succeeded in adapting to the unforeseen obstacles that cropped up and went on producing, carefully selecting areas of research compatible with the means and structures available.
I regard this point as deserving particular attention. Bovet was an empiricist capable of building and setting up various pieces of scientific apparatus with his own hands and a realist aware both of what could be done in a given situation and of what would instead cause too many problems. His scientific choices also reflect this aspect, i.e. his ability to select areas of research where it was possible to compete with groups far better endowed in terms of funds, organization and human resources not head-on but through innovation, scientific biicolage and creativity. In any case, it was essential for Bovet to press forward and overcome all possible obstacles in that science was central to his system of values. His book ends with the following words:
My generation unhesitatingly followed the enlightened conception of science as a source of progress, as being good by definition, and my opinion remains unchanged despite the terrible applications that have marked our century in the field of physics. While it does not appear possible as yet to conceive of a consistent and flawless system of scientific thought at the levels of logic and ethics, it would in any case make no sense to believe that wisdom lies in a deliberate return towards the irrational.
Though our knowledge may be fragmentary, though research may at times have been a source of suffering, this is certainly no reason to accept a culture of ignorance.
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